scholarly journals Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor.

1994 ◽  
Vol 180 (2) ◽  
pp. 757-762 ◽  
Author(s):  
W R Godfrey ◽  
F F Fagnoni ◽  
M A Harara ◽  
D Buck ◽  
E G Engleman
Keyword(s):  
T Cell ◽  
Tumor Necrosis Factor ◽  
T Cell Activation ◽  
Tumor Necrosis ◽  
Cell Activation ◽  
Cd4 T Cell ◽  
Soluble Form ◽  
Extracellular Region ◽  
Human T Cell ◽  
Necrosis Factor

The human OX-40 cell surface antigen is a CD4+ T cell activation marker that acts as a costimulatory receptor and is a member of the nerve growth factor receptor/tumor necrosis factor (TNF) receptor family. Using a soluble form of the receptor, the extracellular region fused with human immunoglobulin Fc, we expression cloned the human OX-40 ligand cDNA from a library derived from an activated B lymphoblastoid cell line MSAB. The encoded protein is identified as gp34, a type II transmembrane antigen previously known to be expressed only by human T cell lymphotropic virus 1-infected cells. We describe gp34 as a new member of the TNF family, and find that the recombinant ligand expressed in COS cells costimulates phorbol myristate acetate, phytohemagglutinin, and anti-CD3-induced CD4+ T cell proliferation.

Synergy of tumor necrosis factor with protein kinase C activators on T cell activation

1990 ◽  
Vol 20 (3) ◽  
pp. 605-610 ◽  
Author(s):  
M. Angeles Muñoz-Fernández ◽  
Felipe X. Pimentel-Muiños ◽  
Miguel A. Alonso ◽  
Miguel Campanero ◽  
Francisco Sánchez-Madrid ◽  
...  
Keyword(s):  
Protein Kinase C ◽  
T Cell ◽  
Protein Kinase ◽  
Tumor Necrosis Factor ◽  
T Cell Activation ◽  
Tumor Necrosis ◽  
Cell Activation ◽  
Kinase C ◽  
Protein Kinase C Activators ◽  
Necrosis Factor

Characterization of individual tumor necrosis factor α- and β-producing cells after polyclonal T cell activation

1989 ◽  
Vol 123 (2) ◽  
pp. 233-240 ◽  
Author(s):  
Ulf Andersson ◽  
Günther Adolf ◽  
Mikael Dohlsten ◽  
Göran Möller ◽  
Hans-Olov Sjögren
Keyword(s):  
T Cell ◽  
Tumor Necrosis Factor ◽  
T Cell Activation ◽  
Tumor Necrosis ◽  
Cell Activation ◽  
Tumor Necrosis Factor Α ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals Boosting Antitumor Response by Costimulatory Strategies Driven to 4-1BB and OX40 T-cell Receptors

2021 ◽  
Vol 9 ◽  
Author(s):  
Daniele E. Mascarelli ◽  
Rhubia S. M. Rosa ◽  
Jessica M. Toscaro ◽  
Isadora F. Semionatto ◽  
Luciana P. Ruas ◽  
...  
Keyword(s):  
T Cells ◽  
T Cell ◽  
Tumor Necrosis Factor ◽  
T Cell Activation ◽  
Tumor Necrosis ◽  
Cell Activation ◽  
Cytotoxic T Lymphocyte ◽  
Tumor Control ◽  
Antitumor Response ◽  
Necrosis Factor

Immunotherapy explores several strategies to enhance the host immune system’s ability to detect and eliminate cancer cells. The use of antibodies that block immunological checkpoints, such as anti–programed death 1/programed death 1 ligand and cytotoxic T-lymphocyte–associated protein 4, is widely recognized to generate a long-lasting antitumor immune response in several types of cancer. Evidence indicates that the elimination of tumors by T cells is the key for tumor control. It is well known that costimulatory and coinhibitory pathways are critical regulators in the activation of T cells. Besides blocking checkpoints inhibitors, the agonistic signaling on costimulatory molecules also plays an important role in T-cell activation and antitumor response. Therefore, molecules driven to costimulatory pathways constitute promising targets in cancer therapy. The costimulation of tumor necrosis factor superfamily receptors on lymphocytes surface may transduce signals that control the survival, proliferation, differentiation, and effector functions of these immune cells. Among the members of the tumor necrosis factor receptor superfamily, there are 4-1BB and OX40. Several clinical studies have been carried out targeting these molecules, with agonist monoclonal antibodies, and preclinical studies exploring their ligands and other experimental approaches. In this review, we discuss functional aspects of 4-1BB and OX40 costimulation, as well as the progress of its application in immunotherapies.

Sign in / Sign up

Export Citation Format

Share Document